Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced the initiation of a Phase II clinical study for a freeze-dried respiratory syncytial virus (RSV) mRNA vaccine, developed by NanoRibo (Shanghai) Biotechnology Co., Ltd., an mRNA vaccine and drug developer that Kanghua Bio plans to acquire. The trial addresses a critical unmet medical need in China, where no RSV vaccine has been approved despite the virus being a leading cause of respiratory infection-related deaths in infants, young children, and elderly populations globally.

Development Program Details

Disease Burden & Market Opportunity

Respiratory syncytial virus (RSV) represents one of the most significant respiratory pathogens worldwide:

• Global Prevalence: Nearly universal infection by age 2; seasonal epidemics annually
• Mortality Impact: Leading cause of respiratory infection-related deaths in vulnerable populations
• Reinfection Risk: Individuals remain susceptible to reinfection throughout life
• Chinese Market Gap: Despite high disease burden, zero approved RSV vaccines currently available in China
• Global Context: Three RSV vaccines approved internationally (GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mRESVIA)

The freeze-dried formulation offers significant logistical advantages for the Chinese market:

• Temperature Stability: Eliminates ultra-cold chain requirements, enabling distribution to rural areas
• Manufacturing Scalability: Compatible with existing vaccine production infrastructure
• Cost Efficiency: Reduced storage and transportation costs compared to liquid mRNA formulations

“This Phase II trial represents a pivotal step toward addressing China’s substantial RSV disease burden,” said Dr. Li Wei, Chief Executive Officer of Chengdu Kanghua. “By combining NanoRibo’s innovative mRNA platform with our established vaccine development and commercialization expertise, we aim to deliver China’s first domestically developed RSV vaccine to protect our most vulnerable populations.”

Strategic Acquisition Rationale

Kanghua’s planned acquisition of NanoRibo reflects a broader industry trend of traditional vaccine manufacturers securing mRNA capabilities:

• Platform Diversification: Expands Kanghua’s portfolio beyond conventional vaccine technologies
• First-Mover Advantage: Positions the company to capture significant market share in China’s RSV vaccine market
• Technology Integration: Leverages NanoRibo’s proprietary freeze-dried mRNA stabilization technology
• Regulatory Pathway: Benefits from China’s accelerated review processes for domestically developed vaccines addressing unmet needs

Industry analysts estimate the Chinese RSV vaccine market could reach ¥8–12 billion ($1.1–1.7 billion) annually once products become available, with domestic manufacturers potentially capturing 60–70% market share due to government procurement preferences and pricing advantages.

Competitive Landscape

While international players have established RSV vaccines globally, Kanghua’s approach offers distinct advantages in the Chinese context:

• Local Manufacturing: Avoids import restrictions and supply chain vulnerabilities
• Pricing Flexibility: Potential for 30–50% lower pricing compared to imported alternatives
• Government Support: Alignment with China’s strategic priorities for vaccine self-sufficiency
• Clinical Development: Trial design optimized for Chinese patient populations and healthcare settings

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, acquisition plans, and market opportunities for RSV vaccines in China. Actual results may vary based on clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech